Supportive treatment of patients with haemopathies relies essentially on transfusion of packed red blood cells and platelets. This transfusion therapy must not escape the PSL prescribing procedures, which remind us that all recommendations must be discussed at each prescribing site with prescribing physicians and haematobiologists. The aim of our retrospective study is to define the epidemioclinical profile of patients in palliative care, to specify the indications and course of transfusion and to estimate the consumption of PSL in 24 patients followed for haemopathies in the palliative treatment stage during the period from June 1, 2018 to December 31, 2018.Our series included 24 patients, 17 of whom were male and 7 female, with a sex ratio of 2.4. The median age was 63.5 years with extremes ranging from 5 to 91 years. At the time of indication for palliative care, 34% of our patients were being followed upfor MDS and 29% for AML. However, multiple myeloma, bone marrow aplasia and ALL were noted in 8.3% of cases.